Amir Fathi

Amir Fathi

Auto-generated profile, based on publicly available information

Amir Fathi

Department of Orthopaedic Surgery, Keck School of Medicine of USC, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2023 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
AFAmir Fathi
Amir Fathi
BBBryan S. Bashrum
Bryan S. Bashrum
MKMichael Sukhyun Kim
Michael Sukhyun Kim
JWJennifer Wang
Jennifer Wang
CMCory K. Mayfield
Cory K. Mayfield
JLJoseph N. Liu
Joseph N. Liu

6 November 2024 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Open access
CMCory K. Mayfield
Cory K. Mayfield
KLKevin C. Liu
Kevin C. Liu
MRMary K. Richardson
Mary K. Richardson
RFRyan D. Freshman
Ryan D. Freshman
JKJacob L. Kotlier
Jacob L. Kotlier
FPFrank A. Petrigliano
Frank A. Petrigliano
Tranexamic acid (TXA) is increasingly utilized in total shoulder arthroplasty (TSA) to minimize blood loss. Despite its benefits, concerns persist regarding its use in patients at elevated risk of postoperative venous thromboembolism (VTE). This study evaluates trends in TXA use and assesses its safety in both general and high-risk patient populations. Patients who underwent primary, elective anatomic TSA and reverse TSA from January 1st, 2016, to December 31st, 2020, were identified using the Premier database. TXA use trends and the proportion of patients requiring blood transfusions were reported. Patients were divided on the basis of having received TXA on the day of surgery or not. To account for confounding variables, a propensity score was generated for the probability of treatment with TXA. A sub analysis of high-risk patients, defined as those with a history of VTE, was performed using multivariable regression analyses. Endpoints included the 90-day risk of pulmonary embolism (PE), deep vein thrombosis (DVT), and transfusion. In total, 86,356 patients underwent TSA from 2016 to 2020. Of these, 41,380 (47.9%) received TXA, and 44,976 (52.1%) did not. After matching, 28,232 received TXA, and 28,232 did not. The use of TXA increased from 33.4% in 2016 to 60.3% in 2020. The rates of transfusion decreased from 1.05% to 0.47%. Following matching, the risk of all thromboembolic complications (odds ratio [OR]: 0.98, 95%-Confidence Interval [CI]: 0.72-1.33, p=0.874), DVT (OR: 1.11, 95%-CI: 0.71-1.71, p=0.655), and PE (OR: 0.87, 95%-CI: 0.56-1.33, p=0.513) were similar between cohorts. The high-risk cohort comprised 4,757 patients with a history of VTE, of which 1,850 (38.9%) received TXA, and 2,907 (61.1%) did not. The use of TXA for high-risk patients increased from 27.4% to 52.0% while rates of transfusion decreased from 1.76% to 0.70%. Following multivariable regression, there was similar risk of all thromboembolic complications (adjusted OR [aOR]: 0.77, 95%-CI: 0.47-1.28, p=0.316), DVT (aOR: 0.96, 95%-CI: 0.39-2.36, p=0.92), and PE (aOR: 0.54, 95%-CI: 0.23-1.28, p=0.163) between high-risk cohorts. TXA in shoulder arthroplasty usage has nearly doubled from 2016 to 2020 and is now administered to 60% of all patients. This rise in TXA use has been coupled with a significant decrease in the risk of blood transfusion. Patients receiving TXA were not at increased risk of thromboembolic, infectious, epileptogenic, surgical, and medical complications even if they had a history of VTE.

17 February 2024 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
JKJacob L. Kotlier
Jacob L. Kotlier
AFAmir Fathi
Amir Fathi
PKPranit Kumaran
Pranit Kumaran
CMCory K. Mayfield
Cory K. Mayfield
MOMadeleine Orringer
Madeleine Orringer
FPFrank A. Petrigliano
Frank A. Petrigliano

25 December 2024 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
CMCory K. Mayfield
Cory K. Mayfield
MAMaya Abu-Zahra
Maya Abu-Zahra
RFRyan Freshman
Ryan Freshman
AFAmir Fathi
Amir Fathi
JKJacob L. Kotlier
Jacob L. Kotlier
FPFrank A. Petrigliano
Frank A. Petrigliano

4 July 2024 in JSES International
Verified
Journal Article
Open access
JCJustin B. Castonguay
Justin B. Castonguay
JKJacob L. Kotlier
Jacob L. Kotlier
AFAmir Fathi
Amir Fathi
FPFrank A. Petrigliano
Frank A. Petrigliano
JLJoseph N. Liu
Joseph N. Liu
Explicit funding and industry affiliation are believed to potentially impact medical research. There have been an increasing number of studies that have evaluated this relationship. The purpose of this study is to determine whether industry affiliation influences the outcomes of randomized controlled trials that investigate the effectiveness of platelet-rich plasma (PRP) in the treatment of lateral epicondylitis. A search of PubMed, SPORTDiscus, and SCOPUS was performed using the search terms “lateral epicondylitis” and “platelet-rich plasma” as well as “tennis elbow” and “platelet-rich plasma.” Only studies from 2010 to present were considered. Final texts were then analyzed for industry affiliation and treatment efficacy. When determining whether a study was industry-affiliated, explicit financial supporters of the study, stated conflicts of interest, American Academy of Orthopaedic Surgeons disclosures, and the Centers for Medicare and Medicaid Services open payments database were assessed. Study outcomes were categorized as favorable, analogous, or unfavorable based on achieving a statistically significant (P < .05) comparison between PRP and control. A total of 26 studies were used. Of these, 20 were industry nonaffiliated and 6 were industry affiliated. There were 15 studies (2 affiliated and 13 nonaffiliated) that reported PRP as favorable compared to the comparison (corticosteroid, analogous whole blood, or normal saline). The endpoints were 6 and 12 months after the use of PRP or the comparison. Quantitative data analysis yielded results that were not statistically significant between industry-nonaffiliated and affiliated groups. The P values for 6-month visual analog scale, 12-month visual analog scale, 6-month disabilities of the arm, shoulder, and hand, 12-month disabilities of the arm, shoulder, and hand, 6-month patient-related tennis elbow evaluation, and 12-month patient-related tennis elbow evaluation were 0.577, 0.635, 0.554, 0.465, 0.273, and 0.157, respectively. Despite our results indicating that industry affiliation does not have an impact on outcomes of randomized controlled trials examining the treatment of lateral epicondylitis with PRP, it is important for future studies to evaluate affiliations when making treatment recommendations.

10 April 2024 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
RFRyan D. Freshman
Ryan D. Freshman
JKJacob L. Kotlier
Jacob L. Kotlier
CMCory K. Mayfield
Cory K. Mayfield
AFAmir Fathi
Amir Fathi
AAAamir Ahmad
Aamir Ahmad
FPFrank A. Petrigliano
Frank A. Petrigliano